What is the standard of care for metastatic Ovarian Cancer according to NCCN guidelines

Standard of Care for Metastatic Ovarian Cancer (NCCN Guidelines)

Based on the NCCN Guidelines Version 3.2025 for Ovarian Cancer, here's what constitutes the standard of care for metastatic (stage IV) disease:

Initial Workup & Assessment

When you're diagnosed with metastatic ovarian cancer, your care team should perform:

Imaging and Staging:

• CT scans of chest, abdomen, and pelvis with contrast (or MRI if you have kidney issues)
• PET/CT scans may be used to evaluate the extent of disease
• These help determine how much cancer is present and where it's located

Laboratory Testing:

• Complete blood count (CBC) and chemistry panel with liver function tests
• CA-125 tumor marker measurement (serves as a baseline for tracking your disease)
• Molecular testing - This is critical for metastatic disease

Molecular Testing (Biomarker Analysis)

According to NCCN Guidelines, tumor tissue analysis should identify:

• BRCA1/2 status (germline and somatic testing)
• HRD (Homologous Recombination Deficiency) status - indicates how well your cancer can repair DNA damage
• HER2 status (by immunohistochemistry)
• MSI (Microsatellite Instability) and MMR (Mismatch Repair) status
• BRAF, FRα (FOLR1), RET, and NTRK mutations if not previously tested

This testing is essential because it directly informs which targeted therapies may work best for your specific cancer.

Primary Treatment Approach

For Stage III-IV Disease:

The standard approach includes:

1. Platinum-Based Chemotherapy - This is the foundation of treatment

   • Typically carboplatin combined with paclitaxel (a chemotherapy drug)
   • Given intravenously (IV) - through a vein
   • Some patients may receive IP (intraperitoneal) chemotherapy - delivered directly into the abdominal cavity
   • For optimally debulked stage III disease, IP therapy has shown median survival of 65.6 months
   • Dose-dense weekly paclitaxel/carboplatin regimens have shown median overall survival of 100.5 months

2. Surgical Debulking - Removing as much visible cancer as possible

   • Typically includes hysterectomy (removal of uterus), bilateral salpingo-oophorectomy (removal of both ovaries and fallopian tubes)
   • Omentectomy (removal of fatty tissue in abdomen where cancer often spreads)
   • Lymphadenectomy (removal of suspicious lymph nodes)
   • Other procedures may include bowel resection, diaphragm stripping, or splenectomy depending on where cancer has spread

Maintenance Therapy (After Initial Chemotherapy Response)

This is a critical part of the standard of care:

PARP Inhibitors - If you achieve a complete or partial response to chemotherapy:

• Recommended for patients with BRCA mutations
• Also considered for patients with HRD-positive tumors (even without BRCA mutations)
• These drugs help prevent cancer cells from repairing DNA damage
• Given as maintenance therapy to extend the time before cancer returns

Bevacizumab - An anti-angiogenesis drug (stops blood vessel formation to tumors)

• May be combined with chemotherapy and continued as maintenance

Monitoring During Treatment

According to NCCN Guidelines, you should expect:

• Physical exams every 1-3 chemotherapy cycles
• CA-125 tumor marker levels checked before each cycle
• Imaging (CT/MRI or PET/CT) as clinically indicated to assess response
• Blood work (CBC and chemistry panels) as needed

Treatment Response Categories

Your doctor will classify your response as:

• Complete Response (CR) - No evidence of disease on imaging
• Partial Response (PR) - Significant tumor shrinkage but some disease remains
• Stable Disease - Cancer neither grows nor shrinks significantly
• Progression - Cancer continues to grow despite treatment

Key Principles from NCCN

The guidelines emphasize that:

• A gynecologic oncologist should be involved in your care planning
• Treatment should be individualized based on your specific tumor characteristics
• Palliative care (symptom management and quality of life support) should be integrated throughout your treatment
• Genetic counseling and testing are important for understanding your options

Questions to Ask Your Oncology Team

1. What is my specific stage and what molecular testing has been done on my tumor?
2. Am I a candidate for both surgery and chemotherapy, or will I receive chemotherapy first (neoadjuvant therapy)?
3. Based on my BRCA and HRD status, which maintenance therapy options are recommended for me?
4. What is the expected timeline for treatment, and how will we monitor my response?
5. What are the potential side effects of my specific chemotherapy regimen, and how will they be managed?
6. Should I be referred to palliative care to help manage symptoms and side effects?

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.

Sources: NCCN Guidelines Version 3.2025 for Epithelial Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer